MX2013014950A - Compuestos para el tratamiento del cancer asociado con el papilomavirus humano. - Google Patents

Compuestos para el tratamiento del cancer asociado con el papilomavirus humano.

Info

Publication number
MX2013014950A
MX2013014950A MX2013014950A MX2013014950A MX2013014950A MX 2013014950 A MX2013014950 A MX 2013014950A MX 2013014950 A MX2013014950 A MX 2013014950A MX 2013014950 A MX2013014950 A MX 2013014950A MX 2013014950 A MX2013014950 A MX 2013014950A
Authority
MX
Mexico
Prior art keywords
compounds
treatment
human papillomavirus
cancers associated
formula
Prior art date
Application number
MX2013014950A
Other languages
English (en)
Inventor
Swati Ajay Piramal
Muralidhara Padigaru
Veena R Agarwal
Gandhali Ashwin Deshpande
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Publication of MX2013014950A publication Critical patent/MX2013014950A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente invento se relaciona con pirrolidiria sustituida por derivados de flavona, representada por los compuestos de la Fórmula (I) o una sal, un solvate, un estereoisómero o un diaestereoisómero farmacéuticamente aceptable de los mismos para uso en el tratamiento de los tipos de cáncer asociados con el papilomavirus humano. El presente invento también se relaciona con las composiciones farmacéuticas que contienen los compuestos de la Fórmula (I) para el tratamiento de los tipos de cáncer asociados con el papilomavirushumano.
MX2013014950A 2011-06-24 2012-06-22 Compuestos para el tratamiento del cancer asociado con el papilomavirus humano. MX2013014950A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161500799P 2011-06-24 2011-06-24
PCT/IB2012/053166 WO2012176163A2 (en) 2011-06-24 2012-06-22 Compounds for the treatment of cancers associated with human papillomavirus

Publications (1)

Publication Number Publication Date
MX2013014950A true MX2013014950A (es) 2014-04-16

Family

ID=46579265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014950A MX2013014950A (es) 2011-06-24 2012-06-22 Compuestos para el tratamiento del cancer asociado con el papilomavirus humano.

Country Status (14)

Country Link
US (5) US20140142159A1 (es)
EP (1) EP2723449A2 (es)
JP (1) JP2014517063A (es)
KR (1) KR20140056227A (es)
CN (1) CN103648588A (es)
AR (1) AR086741A1 (es)
AU (1) AU2012274990A1 (es)
BR (1) BR112013033311A2 (es)
CA (1) CA2840017A1 (es)
MX (1) MX2013014950A (es)
RU (1) RU2014102089A (es)
TW (1) TW201302735A (es)
WO (1) WO2012176163A2 (es)
ZA (1) ZA201400488B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103648588A (zh) * 2011-06-24 2014-03-19 皮拉马尔企业有限公司 治疗人类乳头状瘤病毒相关癌症的化合物
AR096892A1 (es) 2013-07-12 2016-02-03 Piramal Entpr Ltd Una combinación farmacéutica para el tratamiento del melanoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884127B2 (en) * 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
DK2046738T3 (da) 2006-06-21 2014-08-04 Piramal Entpr Ltd Enantiomerisk rene flavonderivativer til behandlingen af proliferative lidelser, samt processer til deres tilberedelse
KR101285957B1 (ko) 2006-07-07 2013-07-12 피라말 엔터프라이지즈 리미티드 플라본으로 치환된 피롤리딘의 광학선택적 합성방법 및 이의 중간체
PT2154971E (pt) * 2007-05-15 2012-04-10 Piramal Life Sciences Ltd Combinação farmacêutica sinérgica para o tratamento de cancro
US20100152129A1 (en) * 2008-03-31 2010-06-17 Periyasamy Giridharan Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer
TWI461194B (zh) * 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
CN103648588A (zh) * 2011-06-24 2014-03-19 皮拉马尔企业有限公司 治疗人类乳头状瘤病毒相关癌症的化合物

Also Published As

Publication number Publication date
CA2840017A1 (en) 2012-12-27
AR086741A1 (es) 2014-01-22
US10098869B2 (en) 2018-10-16
EP2723449A2 (en) 2014-04-30
CN103648588A (zh) 2014-03-19
US11160789B2 (en) 2021-11-02
US20170189378A1 (en) 2017-07-06
WO2012176163A3 (en) 2013-02-21
TW201302735A (zh) 2013-01-16
US20180369200A1 (en) 2018-12-27
US20140142159A1 (en) 2014-05-22
KR20140056227A (ko) 2014-05-09
RU2014102089A (ru) 2015-07-27
BR112013033311A2 (pt) 2017-08-22
JP2014517063A (ja) 2014-07-17
US20220023263A1 (en) 2022-01-27
US20200289465A1 (en) 2020-09-17
US10688079B2 (en) 2020-06-23
WO2012176163A2 (en) 2012-12-27
AU2012274990A1 (en) 2014-02-06
ZA201400488B (en) 2014-11-26

Similar Documents

Publication Publication Date Title
MX2012012571A (es) Dicarboxamidas de ciclopropilo y analogos que muestran actividades anti-cancerosas y anti-proliferativas.
PH12014502605A1 (en) Uracyl spirooxetane nucleosides
MX2015018048A (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
HK1149258A1 (en) Compounds
IN2014MN02106A (es)
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
TN2015000034A1 (en) Derivatives of azaindazole or diazaindazole type for treating pain
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
NZ608116A (en) Triazine-oxadiazoles
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2014012695A (es) Derivados de isoindolona.
IN2015DN01119A (es)
IN2014MN02598A (es)
EA201591195A1 (ru) Новые хинолоновые производные
AU2012214029A8 (en) Rorgammat inhibitors
IN2012DN03182A (es)
MY187718A (en) Pharmaceutical formulations
IN2012DN02139A (es)
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
MX364400B (es) Compuestos de tetraciclina.
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
MX355072B (es) Derivados de riperidina 3-espirociclicos como antagonistas de los receptores de grelina.
IN2012DN02816A (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal